Advertisement
Advertisement
SMMT
Summit Therapeutics Inc. Common Stock
13.36
USDSponsored
+0.63
+4.95%
Aug 25, 15:59 UTC -4
Closed
After-Market
13.72
+0.36
+2.72%
SMMT Earnings Reports
Positive Surprise Ratio
SMMT beat 4 of 16 last estimates.
25%
Next Report
Date of Next Report
Oct 19, 2026
Estimate for Q3 26 (Revenue/ EPS)
$72.86K
/-$0.29
Implied change from Q2 26 (Revenue/ EPS)
--
/+3.57%
Implied change from Q3 25 (Revenue/ EPS)
--
/-6.45%
Summit Therapeutics Inc. Common Stock earnings per share and revenue
On Jul 23, 2026, SMMT reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.28 USD, resulting in a 1.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.81% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.29 USD, with revenue projected to reach 72.86 thousand USD, implying an increase of 3.57% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Summit Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Summit Therapeutics Inc. Common Stock reported EPS of -$0.28, beating estimates by 1.72%, and revenue of $0.00, 0% as expectations.
How did the market react to Summit Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -8.81%, changed from $14.98 before the earnings release to $13.66 the day after.
When is Summit Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 19, 2026.
What are the forecasts for Summit Therapeutics Inc. Common Stock's next earnings report?
Based on --
analysts, Summit Therapeutics Inc. Common Stock is expected to report EPS of -$0.29 and revenue of $72.86K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement